These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38916811)

  • 1. Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma.
    Wu J; Ghobadi A; Maziarz R; Patel K; Hsu H; Liu Z; Sheetz C; Kardel P; Fu C
    Adv Ther; 2024 Aug; 41(8):3232-3246. PubMed ID: 38916811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
    Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
    Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
    Maziarz RT; Yang H; Liu Q; Wang T; Zhao J; Lim S; Lee S; Dalal A; Bollu V
    Leuk Lymphoma; 2022 Sep; 63(9):2052-2062. PubMed ID: 35422192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel versus Tisagenlecleucel in the Treatment of Diffuse Large B-cell Lymphoma Based on a Real-World French Registry.
    Ray M; Castaigne JG; Zang A; Patel A; Hancock E; Brighton N; Bachy E
    Adv Ther; 2024 Nov; 41(11):4282-4298. PubMed ID: 39316290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
    Oluwole OO; Neelapu SS; Ray MD; Limbrick-Oldfield EH; Wade SW; Kanters S; Patel AR; Locke FL
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):457-465. PubMed ID: 38646700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
    Lyman GH; Nguyen A; Snyder S; Gitlin M; Chung KC
    JAMA Netw Open; 2020 Apr; 3(4):e202072. PubMed ID: 32250433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
    Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
    J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis.
    Wu W; Zhou Y; Wang Y; Keramat SA; Balasooriya NN; Zhao Z; Yang Y; Comans T; Dong H
    Appl Health Econ Health Policy; 2023 Sep; 21(5):773-783. PubMed ID: 37356080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.
    Badaracco J; Gitlin M; Keating SJ
    Transplant Cell Ther; 2023 Jan; 29(1):59.e1-59.e6. PubMed ID: 36272529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
    Oluwole OO; Ray MD; Davies N; Bradford R; Jones C; Patel AR; Locke FL
    J Med Econ; 2024; 27(1):230-239. PubMed ID: 38240256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Jacobson CA; Munoz J; Sun F; Kanters S; Limbrick-Oldfield EH; Spooner C; Mignone K; Ayuk F; Sanderson R; Whitmore J; Wang Y; Xu H; Dickinson M
    Transplant Cell Ther; 2024 Jan; 30(1):77.e1-77.e15. PubMed ID: 37890589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
    Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
    Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
    Keating SJ; Gu T; Jun MP; McBride A
    Transplant Cell Ther; 2022 Jul; 28(7):404.e1-404.e6. PubMed ID: 35354101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan.
    Tsutsué S; Makita S; Asou H; Matsuda H; Yamaura R; Taylor TD
    Future Oncol; 2024; 20(19):1333-1349. PubMed ID: 38597742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy - a retrospective cohort study using CMS 100% Medicare claims database.
    Yang H; Bollu V; Lim S; Tesfaye M; Dalal AA; Lax A; Sethi S; Zhao J
    Leuk Lymphoma; 2023 Feb; 64(2):339-348. PubMed ID: 36408973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel CAR T cell therapies for patients with large B cell lymphoma.
    Goto H; Onozawa M; Teshima T
    Int J Hematol; 2024 Jul; 120(1):6-14. PubMed ID: 38795249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
    Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
    J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
    Kelkar AH; Cliff ERS; Jacobson CA; Abel GA; Dijk SW; Krijkamp EM; Redd R; Zurko JC; Hamadani M; Hunink MGM; Cutler C
    Ann Intern Med; 2023 Dec; 176(12):1625-1637. PubMed ID: 38048587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.
    Parker C; Liu FF; Deger KA; Franco-Villalobos C; Proskorovsky I; Keating SJ; Sorensen S
    Adv Ther; 2023 May; 40(5):2355-2374. PubMed ID: 36947328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
    St-Pierre F; Gordon LI
    Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.